T1	Participants 161 271	Breakthrough cancer pain (BTcP) represents an important clinical challenge in the care of patients with cancer
T2	Participants 493 653	This was a randomized, placebo-controlled, multi-center, phase III trial, conducted in opioid-tolerant male and female patients (aged > or =17 years) with BTcP.
